Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases
Medicina · 2024
DOI: 10.3390/medicina60040662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicina, 2024. Verfasst von Jelena Ostojic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University in Novi Sad, 21000 Novi Sad, Serbia. Hauptthemen laut MEDLINE: Aspartic Acid, Brain Neoplasms, Magnetic Resonance Spectroscopy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pokrajinski Sekretarijat za Nauku i Tehnološki Razvoj, Provincial Secretariat for Higher Education and Scientific Research, Autonomous Province of Vojvodina, Republic of Serbia.
Abstract (Originalsprache)
Background and Objectives: Differentiating between a high-grade glioma (HGG) and solitary cerebral metastasis presents a challenge when using standard magnetic resonance imaging (MRI) alone. Magnetic resonance spectroscopy (MRS), an advanced MRI technique, may assist in resolving this diagnostic dilemma. N-acetylaspartate (NAA), an amino acid found uniquely in the central nervous system and in high concentrations in neurons, typically suggests HGG over metastatic lesions in spectra from ring-enhancing lesions. This study investigates exceptions to this norm. Materials and Methods: We conducted an MRS study on 49 histologically confirmed and previously untreated patients with brain metastases, employing single-voxel (SVS) techniques with short and long echo times, as well as magnetic resonance spectroscopic imaging (MRSI).
Results
In our cohort, 44 out of 49 (90%) patients demonstrated a typical MR spectroscopic profile consistent with secondary deposits: a Cho peak, very low or absent Cr, absence of NAA, and the presence of lipids. A peak at approximately 2 ppm, termed the “NAA-like peak”, was present in spectra obtained with both short and long echo times. Among the MRS data from 49 individuals, we observed a peak at 2.0 ppm in five brain metastases from mucinous carcinoma of the breast, mucinous non-small-cell lung adenocarcinoma, two metastatic melanomas, and one metastatic non-small-cell lung cancer. Pathohistological verification of mucin in two of these five cases suggested this peak likely represents N-acetyl glycoproteins, indicative of mucin expression in cancer cells.
Conclusions
The identification of a prominent peak at 2.0 ppm could be a valuable diagnostic marker for distinguishing single ring-enhancing lesions, potentially associated with mucin-expressing metastases, offering a new avenue for diagnostic specificity in challenging cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University in Novi Sad, 21000 Novi Sad, Serbia.
- Special Hospital for Cerebrovascular Diseases "Sveti Sava", 11000 Belgrade, Serbia.
ORCID-Profile: Jelena Ostojic, Dusko Kozic, Aleksandra Lovrenski, Jasmina Boban
Förderung
- Pokrajinski Sekretarijat za Nauku i Tehnološki Razvoj
- Provincial Secretariat for Higher Education and Scientific Research, Autonomous Province of Vojvodina, Republic of Serbia
Zitieren
APA
Ostojic, J., Kozic, D., Panjkovic, M., Georgievski-Brkic, B., Dragicevic, D., Lovrenski, A., & Boban, J. (2024). Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases. Medicina. https://doi.org/10.3390/medicina60040662
Vancouver
Ostojic J, Kozic D, Panjkovic M, Georgievski-Brkic B, Dragicevic D, Lovrenski A, et al. Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases. Medicina. 2024. doi:10.3390/medicina60040662
BibTeX
@article{Ostojic2024,
author = {Ostojic, Jelena and Kozic, Dusko and Panjkovic, Milana and Georgievski-Brkic, Biljana and Dragicevic, Dusan and Lovrenski, Aleksandra and Boban, Jasmina},
title = {Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases},
journal = {Medicina},
year = {2024},
doi = {10.3390/medicina60040662}
}
EUVIMED